{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:09:04Z","timestamp":1783973344680,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtha.2025.12.029","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:46:01Z","timestamp":1777923961000},"page":"1938-1940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cA phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease\u201d: comment"],"prefix":"10.1016","volume":"24","author":[{"given":"Michelle","family":"Hyde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-6776","authenticated-orcid":false,"given":"Madhvi","family":"Rajpurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.12.029_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jtha.2025.07.013","article-title":"A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease","volume":"24","author":"Susen","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.029_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0044-1787662","article-title":"Emicizumab in type 3 von Willebrand disease: report of a case with an alloantibody and literature review","volume":"51","author":"Giuffrida","year":"2025","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.12.029_bib3","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1016\/j.jtha.2023.09.009","article-title":"Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa","volume":"21","author":"Ryu","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.029_bib4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jth.15247","article-title":"Von Willebrand disease type 2N: an update","volume":"19","author":"Seidizadeh","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.029_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.12.029_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17474086.2025.2504956","article-title":"Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in the United States","volume":"18","author":"Roberts","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2025.12.029_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102719","article-title":"Efficacy and safety of plasma-derived von Willebrand factor\/factor VIII concentrate (wilate) prophylaxis in children and adolescents with von Willebrand disease - WIL-31 study post hoc analysis","volume":"9","author":"Sidonio","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.029_bib8","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jtha.2024.06.020","article-title":"Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs","volume":"22","author":"Daniel","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.12.029_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2013-11-540534","article-title":"A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice","volume":"124","author":"Yee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.12.029_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa2312611","article-title":"Efanesoctocog alfa prophylaxis for children with severe hemophilia A","volume":"391","author":"Malec","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362600053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362600053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:56:21Z","timestamp":1783972581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362600053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S153878362600053X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.12.029","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cA phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease\u201d: comment","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.07.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}